BRCA2 and breast cancer: The 192 patients described in this study represent > 90% of the patients diagnosed with BC at TOBH during a 4-year period; yet the sample size was too small to allow for the analysis of possible underuse of RT in patients with PGVs in BRCA1 or BRCA2. In addition, the recent diagnosis and treatment of this study population (2019–2022) precluded the ability to evaluate whether GGT-informed treatments reduce BC survival disparities that characterize patients living in rural areas.